Osteosarcoma Market size was estimated at over USD 800 million in 2024 and is poised to reach USD 1.7 billion by the end of 2037, expanding at a CAGR of 6.5% during the forecast timeline, i.e., 2025-2037. In 2025, the industry size of osteosarcoma is assessed at USD 852 million.
The increasing prevalence of cancer in the pediatric and adolescent populations is one of the drivers in the osteosarcoma market. Despite being a rare chronic condition, the targeted demography of this disease is a major health concern, affecting the well-being of future generations. According to NLM data, published in June 2022, 8,774,979.1 incident cases and 8,956,583.8 prevalent cases of cancer in children under 5 years were reported globally in 2019. The report further states, that around 80% of these childhood cancer cases can be successfully diagnosed and treated with proper healthcare arrangements. Thus, it is dragging the focus of the oncology industry on developing effective treatment and diagnostic solutions, driving growth in this sector.
Further, the high mortality and severity of such bone cancers in children is a strong propelling force behind the innovations in the osteosarcoma market. According to a study report, released in August 2021, the occurrence of malignant bone tumors (MBT) among children younger than 15 accounts 3-5%, which doubles by 7-8% for adolescents aged between 15-19. The study also showcased death events due to osteosarcoma being 37.5% within one year after diagnosis. The growing awareness about early detection pushes healthcare organizations to facilitate efficient devices and tools for better patient outcomes. In addition, the growing investment in R&D for advancements in oncology is creating a new pathway for this sector by introducing more effective bio-based and hybrid therapies.
Growth Drivers
Challenges
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
6.5% |
|
Base Year Market Size (2024) |
USD 800 million |
|
Forecast Year Market Size (2037) |
USD 1.7 billion |
|
Regional Scope |
|
Type (Intramedullary Osteosarcoma, Juxtacortical Osteosarcoma, Extraskeletal Osteosarcoma)
Based on type, the intramedullary osteosarcoma segment is predicted to dominate osteosarcoma market share of over 84.1% by 2037. The segment is driven by the higher incidence rate of this type of MBTs. According to NLM data, published in December 2024, around 80% of the total osteosarcoma cases are reported to be high-grade intramedullary osteosarcoma. The malignancies mostly comprise long bones such as the femur, tibia, and humerus, among which 75-90% occur near the distal femoral, proximal tibial, or proximal humeral physis. Being such common in adolescents and younger adults (less than 25 years aged) puts it on prime focus of healthcare institutions to cultivate solutions.
End user (Hospitals & Clinics, Diagnostic Centers, Academic & Research Organizations)
In terms of end user, the hospitals and clinics segment is estimated to hold a significant share of the osteosarcoma market during the forecast period. The widespread of cancer hospitals and clinics across the world is fueling growth in this segment. The presence of qualified professionals and adequate infrastructure further increases investments in this sector by accommodating advanced diagnostic and treatment solutions. Besides government financing, the increased public expenditure on hospitals is also boosting demand in this segment. Moreover, the improved survival rates and surgical outcomes due to the availability of needed facilities have made hospitals a preferable option for patients to opt for treatment.
Our in-depth analysis of the global market includes the following segments:
|
Type |
|
|
End user |
|
|
Diagnosis & Treatment |
|
North America Market Analysis
North America osteosarcoma market is predicted to hold revenue share of more than 47.6% by 2037. Continuous efforts to improve healthcare infrastructure are garnering a progressive environment for the oncology industry of this region. This is further propagating the regional progress in cancer care. Moreover, the wide network of cancer care centers across developing countries such as the U.S. and Canada is creating a more effective product line for this market. According to a report published by the National Cancer Institute (NCI) of the U.S., in December 2024, around 72 NCI-registered cancer care centers are situated in 36 states and the District of Columbia. The report further estimated that around 400,000 patients receive proper diagnosis from these institutions.
The U.S. is augmenting the regional growth in the osteosarcoma market with the advancement in oncology. The continuous discoveries from research institutions and academic organizations feedstock this sector with a diverse range of solutions. For instance, in August 2024, a clinical trial for immunotherapy afamitresgene autoleuecel led by Memorial Sloan Kettering Cancer Center received approval from the FDA. The newly introduced drug, Tecelra is capable of offering treatment for soft tissue cancers in adults.
Canada is proactively providing financial support to the domestic osteosarcoma market by investing in R&D to save children and adolescents from such life-threatening diseases. For instance, in January 2023, the national public health governing associations of this country allocated a grant of USD 23 million for building the Canadian Pediatric Cancer Consortium (CPCC). The joint initiative was aimed at leveraging domestic childhood cancer research, to help treat the increasing amount of child cancer patients.
APAC Market Statistics
Asia Pacific is poised to register a significant growth rate in the osteosarcoma market during the forecast timeline. Rising efforts from developing countries such as Japan, China, and India to elevate healthcare facilities, delivering better cancer care services. Collaborative government and private initiatives are further inspiring global leaders to participate in this landscape. Furthermore, accumulative healthcare expenditures in Western Pacific countries are presenting lucrative opportunities for this sector.
India is strengthening its foundation in the osteosarcoma market with its strong emphasis on the oncology industry. The governing bodies of this country are actively taking part in spreading awareness about such rare chronic diseases by promoting available treatment options. According to a PIB report, published in February 2023, the central government of India issued the Strengthening of Tertiary Cancer Care Centres Facilities Scheme to empower cancer care. A total of 19 State Cancer Institutes (SCIs) and 20 Tertiary Care Cancer Centres (TCCCs) were approved under this scheme.
China is establishing its leadership in the global osteosarcoma market by supplying high-quality oncology drugs. The manufacturing capabilities of this country is focusing on reducing economic burden by availing affordable treatment options in this sector. According to the NLM article, published in July 2022, 45 anticancer drugs were approved in China between the timeline, 2012-2021. HER2 was among the most commonly developed targets, which were further proven to have the potential to treat such bone cancers.
Global leaders in the market are increasingly investing in drugs and therapy development for cancer treatment. They are now targeting rare types of chronic conditions including pediatric MBTs to expand their portfolio. This is expanding the marketplace by availing revolutionizing solutions in oncology. For instance, in March 2023, Pfizer announced an investment of USD 43 billion to acquire Seagen to globalize innovative cancer medicines. The company aimed at broadening its product pipeline toward transformative cancer therapeutics by cultivating bigger financial resources in this field. Such key players include:
Author Credits: Radhika Pawar
Copyright © 2025 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?